Posted by Michael Wonder on 17 Jul 2024
Health Canada authorizes Alecensaro (alectinib) as the first and only adjuvant treatment for people with ALK positive early stage lung cancer
16 July 2024 - Alecensaro reduced the risk of disease recurrence or death by 76% in people with ALK positive resected non-small cell lung cancer, as demonstrated in the Phase 3 ALINA study.
Roche Canada is pleased to announce that on 27 June 2024, Health Canada granted approval of Alecensaro (alectinib) monotherapy as adjuvant treatment following tumour resection for patients with stage IB (tumours ≥ 4 cm) to IIIA anaplastic lymphoma kinase positive non-small cell lung cancer.
